NEW YORK – Biocept said on Tuesday that it will collaborate with Protean BioDiagnostics to research the ability of Biocept's Target Selector molecular assay to determine EGFR status in non-small cell lung cancer patients.
The research will be conducted in an independent pathology laboratory. Protean BioDiagnostics also expects to validate the analytical performance of a laboratory-developed test based on Biocept's EGFR assay test kit in accordance with the requirements of the College of American Pathologists' validation process.